Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $7.15 USD
Change Today +0.83 / 13.05%
Volume 7.5M
ARRY On Other Exchanges
Symbol
Exchange
NASDAQ GM
As of 8:10 PM 05/4/15 All times are local (Market data is delayed by at least 15 minutes).

array biopharma inc (ARRY) Snapshot

Open
$7.13
Previous Close
$6.32
Day High
$7.40
Day Low
$6.75
52 Week High
03/5/15 - $8.59
52 Week Low
10/13/14 - $2.98
Market Cap
998.1M
Average Volume 10 Days
2.0M
EPS TTM
$-0.44
Shares Outstanding
139.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ARRAY BIOPHARMA INC (ARRY)

array biopharma inc (ARRY) Related Bloomberg News

View More Bloomberg News

array biopharma inc (ARRY) Related Businessweek News

No Related Businessweek News Found

array biopharma inc (ARRY) Details

Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific. The company’s products in Phase III clinical trials include Binimetinib and Encorafenib for the treatment of cancer. Its clinical programs in Phase II clinical trial include ARRY-797, a p38 program for Lamin A/C-related dilated cardiomyopathy; and ARRY-502, a CRTh2 antagonist to treat Th2-driven allergic disease. The company’s proprietary programs also comprise Filanesib, a kinesin spindle protein inhibitor for multiple myeloma; and ARRY-614, a p38/Tie2 dual inhibitor for myelodysplastic syndromes. Its partnered clinical programs include various drug candidates; Selumetinib, an MEK inhibitor for cancer; ASLAN001/ARRY-543, an HER2/EGFR inhibitor for gastric cancer; Ipatasertib/GDC-0068, an AKT inhibitor for cancer; VTX-2337, a toll-like receptor for cancer; and Danoprevir, a Hepatitis C virus protease inhibitor. The company’s partnered clinical programs also comprise LY2606368, an Chk-1 inhibitor for cancer; GDC-0575, an Chk-1 inhibitor for cancer; ARRY-380/ONT-380, an HER2 inhibitor for breast cancer,; GDC-0994, an ERK inhibitor for cancer; and LOXO-101, an PanTrk inhibitor for cancer. It has collaborations with Celgene Corporation; Celgene Alpine Investment Co., LLC; Genentech, Inc.; Loxo Oncology, Inc; Novartis International Pharmaceutical Ltd.; and Oncothyreon Inc. The company was founded in 1998 and is headquartered in Boulder, Colorado.

198 Employees
Last Reported Date: 08/15/14
Founded in 1998

array biopharma inc (ARRY) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $548.8K
Chief Operating Officer
Total Annual Compensation: $343.8K
Compensation as of Fiscal Year 2014.

array biopharma inc (ARRY) Key Developments

Array BioPharma, Inc., Q3 2015 Earnings Call, May 04, 2015

Array BioPharma, Inc., Q3 2015 Earnings Call, May 04, 2015

Array BioPharma, Inc. to Report Q3, 2015 Results on May 04, 2015

Array BioPharma, Inc. announced that they will report Q3, 2015 results on May 04, 2015

Array BioPharma, Inc. Announces Executive Changes

Array BioPharma, Inc. announced that Andrew Robbins, Array's senior vice president of commercial operations, has been appointed as chief operating officer, with responsibility for sales, marketing, manufacturing and business development activities at Array. In this expanded role, Mr. Robbins will be instrumental in ensuring successful commercialization of binimetinib and encorafenib. The company also announced that Dr. David Snitman, chief operating officer, has announced his intention to retire at the end of June 2015. Until that time, Dr. Snitman will serve as executive vice president of business development.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ARRY:US $7.15 USD +0.83

ARRY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Arena Pharmaceuticals Inc $4.31 USD -0.03
CTI BioPharma Corp $1.84 USD +0.05
Evotec AG €3.90 EUR +0.029
Exelixis Inc $2.94 USD +0.11
Progenics Pharmaceuticals Inc $5.30 USD +0.06
View Industry Companies
 

Industry Analysis

ARRY

Industry Average

Valuation ARRY Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 18.1x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 13.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ARRAY BIOPHARMA INC, please visit www.arraybiopharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.